Drug & intervention

paclitaxel

RxCUI 56946

Clinical trials1,088
Recruiting96
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Paclitaxel

Paclitaxel, an alkaloid derived from the Pacific yew, and sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection. There is also an albumin-bound formulation. Common side effects include hair loss, bone marrow suppression, numbness, allergic reactions, muscle pains, and diarrhea. Other side effects include heart problems, increased risk of infection, and lung inflammation. There are concerns that use during pregnancy may cause birth defects. Paclitaxel is in the taxane family of medications. It works by interference with the normal function of microtubules during cell division. Paclitaxel was isolated in 1971 from the Pacific yew and approved for medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It has been made from precursors, and through cell culture.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757 · 2026-09-17
RECRUITING
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10
RECRUITING
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast CancerNCT07768436 · 2026-08-11
RECRUITING
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeNCT07341867 · 2026-07-30
RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · 2026-07-27
RECRUITING
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)NCT07648914 · 2026-07-06
RECRUITING
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerNCT07662395 · 2026-05-09
RECRUITING
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast CancerNCT07396324 · 2026-05-01
RECRUITING
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%NCT07020065 · 2026-04-10
RECRUITING
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)NCT07283692 · 2026-03-01
RECRUITING
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerNCT07377643 · 2026-02-10
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19
RECRUITING
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02
RECRUITING
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLCNCT07309952 · 2025-12-31
RECRUITING
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)NCT07221474 · 2025-12-12
RECRUITING
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 · 2025-12-10
RECRUITING
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedNCT06908993 · 2025-12-09
RECRUITING
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24
RECRUITING
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNCT07229729 · 2025-11-24
RECRUITING
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17
RECRUITING
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerNCT06656598 · 2025-11-07
RECRUITING
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast CancerNCT06492759 · 2025-10-22
RECRUITING
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer PatientsNCT06845319 · 2025-10-20
RECRUITING
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381 · 2025-09-24
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11
RECRUITING
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCNCT07016399 · 2025-09-09
RECRUITING
PALACE: Cemiplimab Trial According to ctDNA LevelsNCT06917573 · 2025-07-29
RECRUITING
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21
RECRUITING
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyNCT07071337 · 2025-07-18
RECRUITING
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)NCT06992882 · 2025-07-08
RECRUITING
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)NCT07153445 · 2025-07-08
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30
RECRUITING
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast CancerNCT06976944 · 2025-06-24
RECRUITING
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13
RECRUITING
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06954246 · 2025-06-04
RECRUITING
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCNCT06364917 · 2025-05-30
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22
RECRUITING
AK129 Combination Therapy for Advanced Solid TumorsNCT06943820 · 2025-05-21
RECRUITING
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · 2025-05-15
RECRUITING
A Study of PHST001 in Advanced Solid TumorsNCT06840886 · 2025-03-31
RECRUITING

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.